---
schema_version: "secwatch.filing_event.v1"
accession: "0001680367-24-000024"
form_type: "8-K"
ticker: "STTK"
cik: "0001680367"
company_name: "Shattuck Labs, Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:37:30.224844+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Shattuck Q1 net loss $18.5M, cash $114.6M; expects data at EHA June 2024

## Summary
- Net loss $18.5M ($0.37 per share) vs $20.7M ($0.49) in Q1 2023; R&D $16.3M, G&A $4.9M.
- Cash and investments $114.6M at March 31, 2024, down from $135.5M a year ago; cash runway into 2026.
- Phase 1B expansion for TP53m AML completed enrollment; randomized HR-MDS cohort expected Q2 2024; data at EHA June 2024.
- Appointed Clay Siegall, Ph.D., and Kate Sasser, Ph.D. to Board of Directors effective March 1, 2024.
- Entered collaboration with Ono Pharma for bifunctional fusion proteins in autoimmune/inflammatory diseases.

## SEC filing metadata
- accession: 0001680367-24-000024
- form_type: 8-K
- ticker: STTK
- cik: 0001680367
- company_name: Shattuck Labs, Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680367/000168036724000024/0001680367-24-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680367/000168036724000024/sttk-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001680367-24-000024
- JSON: https://secwatch.observer/filing/0001680367-24-000024.json
- Plain text: https://secwatch.observer/filing/0001680367-24-000024.txt

## Key facts
- Earnings Releases
  Shattuck Labs, Inc. reported the quarter ended March 31, 2024 results: net income Net loss was $18.5 million for the quarter ended March 31, 2024, or $0.37 per basic and diluted share, EPS $0.37 per basic and diluted share.
  - Period: the quarter ended March 31, 2024
  - Net income: Net loss was $18.5 million for the quarter ended March 31, 2024, or $0.37 per basic and diluted share
  - EPS: $0.37 per basic and diluted share
  - Result: reported results
  source text: Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the quarter ended March 31, 2024 and provided recent business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680367/000168036724000024/0001680367-24-000024-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.